Denes Zadori
Denes Zadori
associate professor in neurology, Department of Neurology, University of Szeged
Verified email at med.u-szeged.hu
Title
Cited by
Cited by
Year
Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells
Z Datki, A Juhász, M Gálfi, K Soós, R Papp, D Zádori, B Penke
Brain research bulletin 62 (3), 223-229, 2003
1652003
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease
D Zádori, G Nyiri, A Szőnyi, I Szatmári, F Fülöp, J Toldi, TF Freund, ...
Journal of neural transmission 118 (6), 865-875, 2011
832011
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease
D Zádori, A Geisz, E Vámos, L Vécsei, P Klivényi
Pharmacology Biochemistry and Behavior 94 (1), 148-153, 2009
832009
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies
D Zádori, P Klivényi, E Vámos, F Fülöp, J Toldi, L Vécsei
Journal of neural transmission 116 (11), 1403-1409, 2009
802009
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders
D Zádori, P Klivényi, L Szalárdy, F Fülöp, J Toldi, L Vécsei
Journal of the neurological sciences 322 (1-2), 187-191, 2012
732012
In vitro model of neurotoxicity of Aβ 1–42 and neuroprotection by a pentapeptide: irreversible events during the first hour
Z Datki, R Papp, D Zádori, K Soós, L Fülöp, A Juhász, G Laskay, ...
Neurobiology of disease 17 (3), 507-515, 2004
642004
Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets
D Zadori, G Veres, L Szalardy, P Klivenyi, J Toldi, L Vecsei
Journal of Alzheimer's Disease 42 (s3), S177-S187, 2014
612014
Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects
L Szalárdy, P Klivényi, D Zádori, F Fulop, J Toldi, L Vécsei
Current medicinal chemistry 19 (13), 1899-1920, 2012
532012
Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives
F Fulop, I Szatmari, E Vamos, D Zadori, J Toldi, L Vécsei
Current medicinal chemistry 16 (36), 4828-4842, 2009
512009
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
D Zádori, P Klivényi, I Plangár, J Toldi, L Vécsei
Journal of cellular and molecular medicine 15 (4), 701-717, 2011
452011
Gray matter is targeted in first-attack multiple sclerosis
SE Schutzer, TE Angel, T Liu, AA Schepmoes, F Xie, J Bergquist, L Vécsei, ...
PloS one 8 (9), e66117, 2013
442013
Manipulating kynurenic acid levels in the brain–on the edge between neuroprotection and cognitive dysfunction
L Szalardy, D Zadori, J Toldi, F Fulop, P Klivenyi, L Vecsei
Current topics in medicinal chemistry 12 (16), 1797-1806, 2012
442012
Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity
L Szalardy, D Zadori, M Simu, K Bencsik, L Vecsei, P Klivenyi
Journal of the neurological sciences 331 (1-2), 38-42, 2013
432013
Alzheimer’s disease: recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines
D Zádori, G Veres, L Szalárdy, P Klivényi, L Vécsei
Journal of Alzheimer's Disease 62 (2), 523-547, 2018
332018
Kynurenines in Parkinson’s disease: therapeutic perspectives
D Zádori, P Klivényi, J Toldi, F Fülöp, L Vécsei
Journal of neural transmission 119 (2), 275-283, 2012
302012
Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy
I Plangár, D Zádori, P Klivényi, J Toldi, L Vécsei
Journal of Alzheimer's Disease 24 (s2), 199-209, 2011
252011
Electron transport disturbances and neurodegeneration: From albert Szent-Györgyi’s concept (Szeged) till novel approaches to boost mitochondrial bioenergetics
L Szalárdy, D Zádori, P Klivényi, J Toldi, L Vécsei
Oxidative medicine and cellular longevity 2015, 2015
232015
Drug-induced movement disorders
D Zádori, G Veres, L Szalárdy, P Klivényi, L Vécsei
Expert Opinion on Drug Safety 14 (6), 877-890, 2015
232015
Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical …
A Fejes-Szabó, Z Bohár, E Vámos, G Nagy-Grócz, L Tar, G Veres, ...
Journal of Neural Transmission 121 (7), 725-738, 2014
212014
Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis
L Szalardy, D Zadori, E Tanczos, M Simu, K Bencsik, L Vecsei, P Klivenyi
Neuroscience Letters 554, 131-134, 2013
212013
The system can't perform the operation now. Try again later.
Articles 1–20